{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HSV-2&page=2",
    "query": {
      "condition": "HSV-2",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HSV-2&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T23:42:45.601Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06698575",
      "title": "A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropositive for HSV-2 With Recurrent Genital Herpes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Genital Herpes Simplex Type 2"
      ],
      "interventions": [
        {
          "name": "ABI-1179",
          "type": "DRUG"
        },
        {
          "name": "ABI-1179 Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Assembly Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 103,
      "start_date": "2024-12-08",
      "completion_date": "2026-01-19",
      "has_results": false,
      "last_update_posted_date": "2026-03-23",
      "last_synced_at": "2026-07-23T23:42:45.601Z",
      "location_count": 4,
      "location_summary": "Kansas City, Missouri • Rochester, New York • Seattle, Washington",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06698575"
    },
    {
      "nct_id": "NCT00655434",
      "title": "HerpeSelect® Express Rapid Test Study Protocol: Sexually Active Adult Population",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Herpes Simplex Virus 2"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Focus Diagnostics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 400,
      "start_date": "2008-03",
      "completion_date": "2008-05",
      "has_results": false,
      "last_update_posted_date": "2009-01-09",
      "last_synced_at": "2026-07-23T23:42:45.601Z",
      "location_count": 1,
      "location_summary": "Burbank, California",
      "locations": [
        {
          "city": "Burbank",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00655434"
    },
    {
      "nct_id": "NCT00231049",
      "title": "Trial Evaluating Safety, Tolerability and Immune Response of AG-707",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Genital Herpes"
      ],
      "interventions": [
        {
          "name": "AG-707",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Agenus Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 35,
      "start_date": "2006-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2008-10-27",
      "last_synced_at": "2026-07-23T23:42:45.601Z",
      "location_count": 3,
      "location_summary": "Indianapolis, Indiana • Portland, Oregon • Seattle, Washington",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00231049"
    },
    {
      "nct_id": "NCT00158860",
      "title": "A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Herpes Genitalis"
      ],
      "interventions": [
        {
          "name": "Valaciclovir",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 384,
      "start_date": "2004-06-21",
      "completion_date": "2006-07-26",
      "has_results": true,
      "last_update_posted_date": "2019-02-15",
      "last_synced_at": "2026-07-23T23:42:45.601Z",
      "location_count": 58,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00158860"
    },
    {
      "nct_id": "NCT00274300",
      "title": "Safety Study of HSV2 DNA Vaccine to Treat Patients With Recurrent Genital Herpes Caused by HSV-2",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HSV-2"
      ],
      "interventions": [
        {
          "name": "pPJV7630 administered by PMED",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "PowderMed",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 36,
      "start_date": "2004-08",
      "completion_date": "2005-07",
      "has_results": false,
      "last_update_posted_date": "2007-01-29",
      "last_synced_at": "2026-07-23T23:42:45.601Z",
      "location_count": 2,
      "location_summary": "Portland, Oregon • Houston, Texas",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00274300"
    },
    {
      "nct_id": "NCT02300142",
      "title": "Rollover Trial for Placebo Subjects Previously Enrolled Into GEN-003-002 Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Genital Herpes Simplex Type 2"
      ],
      "interventions": [
        {
          "name": "GEN-003 Vaccine (30μg of each antigen)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GEN-003 Vaccine (60μg of each antigen)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Matrix-M2 Adjuvant (25μg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Matrix-M2 Adjuvant (50μg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Matrix-M2 Adjuvant (75μg)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Genocea Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 37,
      "start_date": "2015-01",
      "completion_date": "2016-06",
      "has_results": false,
      "last_update_posted_date": "2017-10-16",
      "last_synced_at": "2026-07-23T23:42:45.601Z",
      "location_count": 16,
      "location_summary": "Birmingham, Alabama • San Diego, California • San Francisco, California + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02300142"
    },
    {
      "nct_id": "NCT00310271",
      "title": "A Safety Study to Assess a DNA Vaccine Administered by Particle Mediated Delivery to the Skin in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HSV-2"
      ],
      "interventions": [
        {
          "name": "pPJV7630 with pPJV2012 administered by PMED",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "PowderMed",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 42,
      "start_date": "2006-04",
      "completion_date": "2006-12",
      "has_results": false,
      "last_update_posted_date": "2008-11-21",
      "last_synced_at": "2026-07-23T23:42:45.601Z",
      "location_count": 1,
      "location_summary": "Lenexa, Kansas",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00310271"
    },
    {
      "nct_id": "NCT00495716",
      "title": "Effect of HSV-2 Suppressive Therapy on Sexual Behavior",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Genital Herpes"
      ],
      "interventions": [
        {
          "name": "acyclovir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2008-01",
      "completion_date": "2010-06",
      "has_results": true,
      "last_update_posted_date": "2023-03-07",
      "last_synced_at": "2026-07-23T23:42:45.601Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00495716"
    },
    {
      "nct_id": "NCT02114060",
      "title": "Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Genital Herpes Simplex Type 2"
      ],
      "interventions": [
        {
          "name": "GEN-003 Vaccine (30μg of each antigen)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GEN-003 Vaccine (60μg of each antigen)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Matrix-M2 Adjuvant (25μg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Matrix-M2 Adjuvant (50μg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Matrix-M2 Adjuvant (75μg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Genocea Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 310,
      "start_date": "2014-07",
      "completion_date": "2016-02",
      "has_results": false,
      "last_update_posted_date": "2017-10-16",
      "last_synced_at": "2026-07-23T23:42:45.601Z",
      "location_count": 16,
      "location_summary": "Birmingham, Alabama • San Diego, California • San Francisco, California + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02114060"
    },
    {
      "nct_id": "NCT00362297",
      "title": "Randomized Trial to Evaluate Suppressive Effect of High-Dose Acyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Genital Herpes"
      ],
      "interventions": [
        {
          "name": "acyclovir",
          "type": "DRUG"
        },
        {
          "name": "valacyclovir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2006-09",
      "completion_date": "2011-09",
      "has_results": true,
      "last_update_posted_date": "2021-11-18",
      "last_synced_at": "2026-07-23T23:42:45.601Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00362297"
    }
  ]
}